|
|
|
Volumn 115, Issue 1155, 2002, Pages 274-275
|
|
PHARMAC and availability of pharmaceuticals (multiple letters) [1]
a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
PAROXETINE;
REBOXETINE;
SEROTONIN UPTAKE INHIBITOR;
TRICYCLIC ANTIDEPRESSANT AGENT;
VENLAFAXINE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DEPRESSION;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
FINANCIAL MANAGEMENT;
HUMAN;
LETTER;
META ANALYSIS;
METHODOLOGY;
PHARMACEUTICAL CARE;
PRESCRIPTION;
RESPONSIBILITY;
SIDE EFFECT;
TREATMENT FAILURE;
TREATMENT OUTCOME;
BIAS (EPIDEMIOLOGY);
COST-BENEFIT ANALYSIS;
CYCLOHEXANOLS;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEW ZEALAND;
PHARMACEUTICAL SERVICES;
RESEARCH SUPPORT;
SEROTONIN UPTAKE INHIBITORS;
|
|
EID: 0037035992
PISSN: 00288446
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (3)
|
|
References (0)
|